Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH.
- Trial name
- NCT00832507
- Testing
- Cicletanine
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 162 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension, Interstitial Lung Disease
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Our hypothesis is that IV or SQ Treprostinil can improve 6 minute walk distance, hemodynamics and quality of life in patients with interstitial lung disease and severe secondary pulmonary arterial hypertension.
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT00705133
- Testing
- Treprostinil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rajan Saggar
Pulmonary Arterial Hypertension
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
- Trial name
- NCT06409026
- Testing
- Sotatercept
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Knowledge Translation Program for the guidelines and evidence-based management of PAH patients
- Trial name
- PAH QuERI Ext (NCT01389206)
- Testing
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 797 people
- Sponsor
- Actelion
Chronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Determinants of Right Heart Remodeling in Patients With CTEPH or PAH
Right heart failure is the main cause of morbi-mortality in patients with pulmonary hypertension (PH), including patients of chronic thrombo-embolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)…
- Trial name
- PRINCEPT (NCT03205085)
- Testing
- magnetic resonance imaging, 2D and 3D trans-thoracic echocardiography, Blood samples
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Arterial Hypertension
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receiving background dual therapy (ambrisentan…
- Trial name
- NCT02999906
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Arterial Hypertension
Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb® Ig flex adsorber treatment (as an add-on to conventional treatment) used exclusively with the LIFE 18® apheresis system for…
- Trial name
- NCT01613287
- Testing
- TheraSorb® - Ig flex
- Where
- 4 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Miltenyi Biotec B.V. & Co. KG
Pulmonary Hypertension
Remote Exercise Program Delivery Using a Mobile Application for Pulmonary Arterial Hypertension
This study will determine the feasibility of a mobile application-based home exercise rehabilitation program for patients with pulmonary hypertension.
- Trial name
- REVAMP (NCT04559516)
- Testing
- Exercise Intervention, Standard Care
- Where
- Canada
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the safety and effectiveness of iloprost for PAH in children who are between the ages of 3 and 18 years old.
- Trial name
- NCT00453414
- Testing
- Iloprost Inhalation Solution (Ventavis)
- Where
- 2 sites in United States
- Sponsor
- Actelion
Hypertension, Pulmonary
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed
Pulmonary arterial hypertension (PAH) is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery (PA) rises above normal levels and may become life threatening.
- Trial name
- CARVE (NCT01121458)
- Testing
- Clevidipine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- North Texas Veterans Healthcare System
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
This single-arm, retrospective study aims to evaluate the safety and efficacy of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (PH).
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Chronic Lung Disease-Associated Pulmonary Hypertension, Lung Transplantation
- Trial name
- NCT06605326
- Testing
- Subcutaneous Treprostinil
- Volunteers
- 46 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Hypertension, Pulmonary
The Effect of Tracleer® on Male Fertility
The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (PAH).
- Trial name
- NCT00082186
- Testing
- bosentan
- Volunteers
- 22 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
- Trial name
- NCT00159861
- Testing
- Sildenafil citrate
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Pulmonary
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.
- Trial name
- NCT00549302
- Testing
- tadalafil
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 357 people
- Sponsor
- Eli Lilly and Company
Heart Failure With Preserved Ejection Fraction, Pulmonary Hypertension
Exercise Right Ventricular Coupling in HFpEF
The investigators aim to evaluate the feasibility and prognostic value of right ventricular-arterial coupling (RVAC) during exercise in patients with HFpEF-PH using a hybrid technique of real-time CMRderived volume measures and…
- Trial name
- ENDURE (NCT05731466)
- Testing
- CardioMems HF System
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Hypertension (PH) Due to Left Heart Disease
TReatment of Pulmonary Hypertension Group II Study
The objective of this study is to assess the safety and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation in group II PH patients through change in clinical parameters including hemodynamics…
- Trial name
- TROPHY-II (NCT03611270)
- Testing
- Pulmonary Denervation
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Pulmonary Hypertension
Non-invasive Assessment of Pulmonary Artery Pressure
The assessment of pulmonary artery pressure (PAP) and parameters describing right ventricular function stand in the focus of the diagnosis and clinical management of pulmonary hypertension (PH).
- Trial name
- NCT02223559
- Where
- Austria
- Volunteers
- 90 people
- Sponsor
- Medical University of Graz
Chronic Thromboembolic Pulmonary Hypertension, Inspiratory Muscle Training
Inspiratory Muscle Training in Pulmonary Hypertension
Inspiratory muscle training for 8 weeks in patients with pulmonary hypertension.
- Conditions
- Chronic Thromboembolic Pulmonary Hypertension, Inspiratory Muscle Training, Inspiratory Muscle Weakness, Pulmonary Arterial Hypertension
- Trial name
- NCT03102294
- Testing
- inspiratory muscle training
- Where
- Brazil
- Volunteers
- 32 people
- Sponsor
- Federal University of São Paulo
Pulmonary Arterial Hypertension
Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Bosentan 32 mg Dispersible Tablets versus Tracleer® 32 mg Tablets for Oral Suspension (Tracleer® 32 mg Dispersible Tablet)…
- Trial name
- NCT06484673
- Testing
- Bosentan Dispersible Tablets, Tracleer Tablet for Oral Suspension
- Where
- Jordan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi